IRA Resource Center
The Inflation Reduction Act (IRA) was signed into law on Aug. 16, 2022. Among the topics covered by the IRA are Medicare price negotiation for qualifying single-source drugs; manufacturer rebates for certain drugs paid under Medicare Parts B or D if their average prices increase faster than the rate of inflation; Part D redesign including eliminating the coverage gap, setting an annual out-of-pocket cap (initially $2,000), limits to premium increases, mandated coverage for vaccines, and a $35 monthly insulin cap. Many questions remain about the implementation of this law, which will be done through agency guidance, program instruction, agreements between CMS and drug manufacturers, and notice-and-comment rulemaking.
Please review the following resources for additional information:
AMCP Resources
- AMCP Statement on the Passage of the Inflation Reduction Act
- Understanding the Fundamentals of IRA and Its Impact, AMCP Nexus Pre-Conference Program
- Keeping Up With IRA at E-Learning Days
- IRA Workshop Series
JMCP Articles on the Drug Price Negotiation Program
- Drugs Likely Subject to Medicare Negotiation, 2026-2028
- Estimated Discounts Generated by Medicare Drug Negotiation in 2026
CMS Resources
- CMS Drug Price Negotiation Timeline for 2026
- ASPE Office of Health Policy: Fact Sheet — Inflation Reduction Act Research Series— Medicare Enrollees’ Use and Out-of-Pocket Expenditures for Drugs Selected for Negotiation under the Medicare Drug Price Negotiation Program
- Inflation Reduction Act and Medicare
- Fact Sheet: Anniversary of the Inflation Reduction Act: Update on CMS Implementation
- Fact Sheet: Medicare Drug Price Negotiation Program Initial Guidance
- Press Release: Inflation Reduction Act Continues to Lower Out-of-Pocket Prescription Drug Costs for Drugs with Price Increases Above Inflation
- FAQs: Reduced Drug Prices, Enhanced Medicare Benefits Under the Inflation Reduction Act
AMCP Regulatory NewsBREAKS
Find IRA-related breaking news on the member-only Regulatory NewsBREAKs page.
Legislation
For questions, please contact Vicky Jucelin.